Dyne Therapeutics Reports Third-Quarter 2026 Financial Results
The report lists a Biologics License Application for z-rostudirsen in exon 51 Duchenne muscular dystrophy among recent business highlights.
Story updates
12:32:32 PM UTC
SquawkNews
Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -- Additional one-year clinical data from Phase 1/2 ACHIEVE trial of z-basivarsen for myotonic dystrophy type 1 (DM1) prese…